C.R. Bard’s responsibility in the injuries caused by the IVC Filters

After a NBC Investigation was conducted, many questions began to arise about the company C.R. Bard. The company is behind the device the Bard G2 IVC Filter, designed to catch blood clots before they travel towards the lungs and cause pulmonary embolism, according to Habush Habush & Rottier S.C. ®. Although the medical device was intended to help individuals looking to prevent the deadly disease, many side effects began to come to light. More than 900 cases of adverse effects caused by the implanting of the temporary device were reported to the FDA, including 27 deaths. Despite these disturbing figures, the company neglected to recall the product.

The failure of C.R. Bard to recall the device meant it was still being used on individuals unaware of the devastating risks associated with the IVC Filter. The device often became fractured inside the body or migrated to other areas of the body, leading to conditions such as cardiac tamponade and perforation of the heart. Not only were individuals put at risk of these conditions, but were not properly warned about these side effects. Numerous lawsuits have begun piling up against the Bard Company, who many suspect knew about the dangerous side effects and failed to warn patients about them. This is not the company’s first run-in with the FDA, as the Bard G2 IVC Filter was a replacement for the Bard Recovery Filter associated with many of the same side effects.

New dangers of the filters are still surfacing, thanks in part to NBC’s yearlong investigation of the company and the device. Individuals are still coming to the forefront reporting their nightmarish encounters after the implanting of the device, including many who narrowly escaped death after the device became lodged in their bodies. Regardless of the warning issued by the FDA, many individuals will continue to suffer from the filter as long as C.R. Bard does not properly handle the dangers associated with the device.

Leave a Reply

Your email address will not be published. Required fields are marked *